Welcome to our dedicated page for PTC THERAPEUTICS SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PTC THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PTC THERAPEUTICS's regulatory disclosures and financial reporting.
PTC Therapeutics, Inc. reported strong Q2 2026 results, with total revenues of $360.5 million, up from $178.9 million a year earlier. Growth was driven by net product revenue of $238.8 million and collaboration and license revenue of $50.6 million, including a $50.0 million milestone from Novartis for Huntington’s disease candidate votoplam. Royalty revenue contributed $71.1 million. Operating income reached $149.0 million and net income attributable to common stockholders was $83.5 million, or diluted EPS of $0.92, versus a prior-year loss.
PTC ended June 30, 2026 with $1.05 billion in cash and cash equivalents and $1.18 billion in marketable securities, against roughly $591 million of debt and a $2.32 billion liability for sale of future Evrysdi royalties, leaving stockholders’ deficit at $165.4 million. In June it issued $550.0 million of 0% convertible senior notes due 2031 and repurchased $222.0 million of its 1.50% notes due 2026, leaving $55.5 million outstanding. Operationally, Sephience for PKU is now approved in the U.S., EU, Japan, Brazil and additional geographies; Novartis commenced a global Phase 3 votoplam trial; PTC initiated a Phase 1 study of PTC612, plans a Phase 2a study of PTC844 and expects to start the PROVE-FA study of vatiquinone in Q3 2026. The company expects product cash flows, Novartis milestones and existing liquidity to fund operations for at least 12 months.
PTC Therapeutics reported strong second-quarter 2026 results, with total revenue of $361 million, including $239 million of product revenue. Sephience generated $151 million of Q2 2026 revenue and had 1,647 patients on commercial therapy worldwide as of June 30, 2026. Total net product and royalty revenue was $309.9 million versus $175.9 million a year earlier, and net income attributable to common stockholders was $83.5 million, compared with a $64.8 million loss in Q2 2025; diluted EPS was $0.92.
The company raised full-year 2026 guidance, targeting total revenue of $1.18 to $1.28 billion and product revenue of $850 to $950 million. Projected 2026 GAAP R&D and SG&A expense is $775 to $815 million, with non-GAAP expected at $680 to $720 million. Cash and marketable securities were about $2.2 billion as of June 30, 2026, with total debt of $590.97 million and a $2.32 billion liability for sale of future royalties.
Pipeline updates included positive 24‑month PIVOT‑HD data for votoplam showing 52% dose‑dependent disease slowing on the cUHDRS at the 10 mg dose in Stage 2 participants, and a Novartis-funded Phase 3 INVEST‑HD trial (~770 patients) that triggered a $50 million milestone payment. PTC named PTC303 as its next MSH3 splicing candidate, initiated Phase 1 for PTC612 and plans a Phase 2a study of PTC844 in Q3 2026. The company also appointed Hege Sollie‑Zetlmayer to its board as a Class III director, granting equity awards under its director compensation policy.
PTC Therapeutics' chief financial officer Pierre Gravier automatically sold 3,494 shares of common stock on July 14, 2026 at $80.35 per share pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 6,500 RSUs from a 26,000 RSU grant. After this transaction, he directly holds 83,986 shares, including 162 shares acquired through the employee stock purchase plan.
PTC Therapeutics director Mary L. Smith exercised stock options for 15,834 shares of common stock at an exercise price of $42.95 per share and sold 15,834 shares in open-market transactions at $90.00 per share on July 9, 2026. The sales were effected pursuant to a written Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, she holds 21,813 shares of PTC Therapeutics common stock directly.
Neil Gregory Almstead, Chief Technical Ops Officer of PTC Therapeutics, exercised stock options to acquire 2,464 common shares at $46.54 and on the same day sold 2,464 shares at a weighted average of $90.25 per share under a pre-arranged Rule 10b5-1 plan. Following these transactions, he holds 60,299 shares directly, 2,899 shares indirectly through his spouse, and 45,036 stock options granted January 3, 2025 that vest over four years and expire January 2, 2035.
Reporting person submitted a Form 144 notice to sell Common stock under Rule 144. The filing lists a planned sale of 2,464 shares on 07/09/2026 in connection with a Stock Option Exercise and multiple reported dispositions by Neil G. Almstead on 06/22/2026 through 07/07/2026 with individual sale amounts shown.
PTC Therapeutics executive Mark Elliott Boulding reported both sales and option exercises in PTC THERAPEUTICS, INC. common stock. On July 6, 2026, he sold 5,079 shares in a series of open‑market transactions at weighted average prices spanning $82.76 to $86.73. These sales were executed under a written Rule 10b5‑1 trading plan adopted on September 10, 2025.
On the same date, he exercised stock options to acquire 5,039 shares at strike prices of $46.54 and $39.42. Following the transactions, Boulding directly owns 105,272 shares of PTC Therapeutics common stock, and the filing shows remaining stock options outstanding in multiple series.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead sold 46,774 shares of common stock in open-market trades while exercising stock options. The sales on July 6–7 were executed under a pre-set Rule 10b5-1 trading plan.
Almstead exercised options to acquire 46,774 shares at exercise prices of $38.10 and $39.42 per share, then sold equivalent amounts at weighted average prices in the mid‑$80s to high‑$80s. Following these transactions, he holds 60,299 shares directly and 2,899 shares indirectly through his spouse.